Halozyme Financial Statements (HALO) |
||||||||||
Halozymesmart-lab.ru | % | 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
---|---|---|---|---|---|---|---|---|---|---|
Report date | 09.05.2023 | 08.08.2023 | 06.11.2023 | 20.02.2024 | 07.05.2024 | 07.05.2024 | ||||
Currency | USD | USD | USD | USD | USD | USD | ||||
Financial report URL | ||||||||||
Revenue, bln rub | ? | 162.1 | 221.0 | 216.0 | 230.0 | 195.9 | 863.0 | |||
Operating Income, bln rub | 53.8 | 94.5 | 88.3 | 101.0 | 95.5 | 379.3 | ||||
EBITDA, bln rub | ? | 71.6 | 115.1 | 108.6 | 121.7 | 115.7 | 461.2 | |||
Net profit, bln rub | ? | 39.6 | 74.8 | 81.8 | 85.4 | 76.8 | 318.8 | |||
OCF, bln rub | ? | 87.0 | 66.8 | 132.4 | 102.4 | 129.4 | 431.0 | |||
CAPEX, bln rub | ? | 11.4 | 1.62 | 2.94 | 2.60 | 3.55 | 10.7 | |||
FCF, bln rub | ? | 75.6 | 68.5 | 129.5 | 99.8 | 125.9 | 423.6 | |||
Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
OPEX, bln rub | 73.2 | 76.5 | 72.9 | 76.7 | 54.2 | 280.4 | ||||
Cost of production, bln rub | 35.2 | 50.1 | 54.8 | 52.3 | 46.1 | 203.3 | ||||
R&D, bln rub | 18.0 | 19.7 | 17.3 | 21.3 | 19.1 | 77.5 | ||||
Interest expenses, bln rub | 4.54 | 4.49 | 4.51 | 5.22 | 4.51 | 18.7 | ||||
Assets, bln rub | 1 699 | 1 810 | 1 893 | 1 733 | 1 842 | 1 842 | ||||
Net Assets, bln rub | ? | 65.9 | 151.0 | 249.2 | 83.8 | 177.8 | 177.8 | |||
Debt, bln rub | 1 494 | 1 496 | 1 498 | 1 499 | 1 533 | 1 533 | ||||
Cash, bln rub | 275.6 | 348.3 | 483.3 | 336.0 | 463.5 | 463.5 | ||||
Net debt, bln rub | 1 219 | 1 148 | 1 014 | 1 163 | 1 069 | 1 069 | ||||
Ordinary share price, rub | 38.2 | 36.1 | 38.2 | 37.0 | 40.7 | 34.3 | ||||
Number of ordinary shares, mln | 135.0 | 131.7 | 132.0 | 129.1 | 126.9 | 126.9 | ||||
Market cap, bln rub | 5 157 | 4 752 | 5 041 | 4 770 | 5 164 | 4 354 | ||||
EV, bln rub | ? | 6 375 | 5 899 | 6 055 | 5 933 | 6 233 | 5 423 | |||
Book value, bln rub | -879 | -777 | -658 | -806 | -694 | -694 | ||||
EPS, rub | ? | 0.29 | 0.57 | 0.62 | 0.66 | 0.61 | 2.51 | |||
FCF/share, rub | 0.56 | 0.52 | 0.98 | 0.77 | 0.99 | 3.34 | ||||
BV/share, rub | -6.51 | -5.90 | -4.99 | -6.24 | -5.47 | -5.47 | ||||
EBITDA margin, % | ? | 44.2% | 52.1% | 50.3% | 52.9% | 59.1% | 53.4% | |||
Net margin, % | ? | 24.4% | 33.8% | 37.9% | 37.1% | 39.2% | 36.9% | |||
FCF yield, % | ? | 5.11% | 6.16% | 7.01% | 7.83% | 8.20% | 9.73% | |||
ROE, % | ? | 275.8% | 154.7% | 101.9% | 336.0% | 179.3% | 179.3% | |||
ROA, % | ? | 10.7% | 12.9% | 13.4% | 16.2% | 17.3% | 17.3% | |||
P/E | ? | 28.4 | 20.3 | 19.9 | 16.9 | 16.2 | 13.7 | |||
P/FCF | 19.6 | 16.2 | 14.3 | 12.8 | 12.2 | 10.3 | ||||
P/S | ? | 7.31 | 6.14 | 6.46 | 5.75 | 5.98 | 5.05 | |||
P/BV | ? | -5.87 | -6.12 | -7.66 | -5.92 | -7.44 | -6.27 | |||
EV/EBITDA | ? | 20.6 | 15.6 | 16.2 | 14.2 | 13.5 | 11.8 | |||
Debt/EBITDA | 3.93 | 3.03 | 2.71 | 2.79 | 2.32 | 2.32 | ||||
R&D/CAPEX, % | 158.0% | 1 215% | 588.3% | 821.9% | 539.1% | 723.7% | ||||
CAPEX/Revenue, % | 7.02% | 0.73% | 1.36% | 1.13% | 1.81% | 1.24% | ||||
Halozyme shareholders |